Ryan Moslin

5PUBLICATIONS
15CO-AUTHORS
Basic pharmacologyAutoimmunityBiologically active moleculesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 19, 2024
Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent.

Murugaiah A M Subbaiah, Thangeswaran Ramar, Maheswara Reddy

|Jul 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.

James R Burke, Lihong Cheng, Kathleen M Gillooly

|Jul 19, 2019
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

Stephen T Wrobleski, Ryan Moslin, Shuqun Lin

|Jul 18, 2019
Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).

Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski

|Aug 16, 2018
Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling.

R Moslin, D Gardner, J Santella

Pageof 1

Frequent Collaborators

3 joint publications

Stephen T Wrobleski

2 joint publications

Percy H Carter

2 joint publications

Steven Spergel

1 joint publications

James R Burke